In today's Pharmaceutical Executive Daily, FDA approves AstraZeneca's Fasenra as a new treatment for hypereosinophilic ...

According to him, the industry must address its relationship with the capital markets, address misinformation issues, and push back against the politicization of medical research and development.

Toragen is uniquely positioned to navigate this dynamic. Its HPV E5 inhibitor addresses indications that span both sexes: HPV-positive head and neck cancer affects predominantly men, cervical cancer ...

Hypereosinophilic syndrome is defined by persistent eosinophilia with eosinophil-mediated organ/tissue damage, driving ...